The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
The Food and Drug Administration has accepted for review the Biologics License Application for AR101 (Aimmune Therapeutics) to reduce the risk of anaphylaxis following accidental exposure to peanut.
A new granule formulation of Prograf (tacrolimus; Astellas) has been made available for the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplant, and heart transplant, in combination with other immunosuppressants.
Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention.
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections, used in combination with metronidazole, and for complicated urinary tract infections.
A preliminary analysis of long-term follow-up data (up to 5 years) involving patients with peripheral arterial disease (PAD) treated with paclitaxel-coated products revealed a ‘potentially concerning’ signal of increased long-term mortality when compared with those treated with uncoated devices, according to the Food and Drug Administration (FDA). Among the 3 trials that included 5-year follow-up…
The American College of Cardiology and American Heart Association have released a new evidence-based guideline detailing the primary prevention of cardiovascular disease.
Non-Caucasian minorities less likely to receive proper supplementation
Men with prediabetes, hypogonadism achieved normal glucose regulation with TTh
Please login or register first to view this content.
